373608-48-1

Basic information

• Product Name: 4-(3-AMINO-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: TERT-BUTYL 4-(3-AMINOPROPYL)PIPERAZINE-1-CARBOXYLATE;4-(3-AMINO-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;BUTTPARK 90\06-06;1-BOC-4-(3-AMINOPROPYL)PIPERAZINE;3-(4-Boc-piperazinyl)propanamine;1-tert-Butyloxycarbonyl-4-(3-aminopropyl)-piperazine;1-Piperazinecarboxylicacid, 4-(3-aMinopropyl)-, 1,1-diMethylethyl ester
• CAS NO: 373608-48-1
• Molecular Formula: C₁₂H₂₅N₃O₂
• Molecular Weight: 243.35
• Product Categories: pharmacetical
• Mol File: 373608-48-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 339.6 °C at 760 mmHg
• Flash Point: 159.2 °C
• Appearance: /
• Density: 1.042±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 9.1E-05mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.39±0.10(Predicted)
• CAS DataBase Reference: 4-(3-AMINO-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-AMINO-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(373608-48-1)
• EPA Substance Registry System: 4-(3-AMINO-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(373608-48-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 373608-48-1(Hazardous Substances Data)

Usage

General Description

4-(3-Amino-propyl)-piperazine-1-carboxylic acid tert-butyl ester is a chemical compound, typically used as an intermediate in the field of organic synthesis. It features a piperazine ring as part of its structure, an organic element often observed in pharmaceuticals due to its ability to improve solubility and absorption in drugs. It is characterized by the presence of both an amine and carboxylic acid ester functional groups. The tert-butyl ester group is commonly used in synthesis as a protecting group for carboxylic acids, as it is easily introduced and removed under standard laboratory conditions. Its applications are mainly seen in research labs to develop new substances or understanding molecular structures and reactions. As with most chemicals, appropriate safety measures are required when handling this compound to prevent direct contact, ingestion, or inhalation.

InChI:InChI=1/C12H25N3O2/c1-12(2,3)17-11(16)15-9-7-14(8-10-15)6-4-5-13/h4-10,13H2,1-3H3

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 946517-70-0 tert-butyl 4-(3-azidopropyl)piperazine-1-carboxylate 
• 603-35-0 triphenylphosphine 
• 857266-28-5 tert-butyl 4-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]piperazine-1-carboxylate 

Downstream Products

• 1278585-02-6 3,3',3,3',3,3'-(3,3',3-(4,4',4-(4,4',4-(4,4',4-(benzene-1,3,5-triyltris(methylene))tris(piperazine-4,1-diyl))tris(butane-4,1-diyl))tris(piperazine-4,1-diyl))tris(propane-3,1-diyl))tris(azanetriyl)hexapropanenitrile 
• 1201691-81-7 4-{3-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-propyl}-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

FGFR4 Inhibitor. Compositions and their use in pharmaceutical preparations

The invention provides 3 inhibitor which takes 4 - 4 dihydropyrimidine [5 - d,2] pyrimidine - (1H) FGFR4 ketone as a mother nucleus and has a covalent structure. The examples give 9 specific compounds and kinase inhibitory activity testing of these 9 compounds, wherein LX08 for FGFR4 kinase inhibitory activity is only 7 nm, lower than FIIN - 2 of the active control, and potential application prospects. In addition, by subjecting the synthesized compound to MALDI-TOF mass spectrometry, we found that compounds of LX01, LX05, LX06, LX07, LX08 are covalently bound to FGFR4 of Cys552, cannot covalently bind FGFR4 of Cys477, and LX09 are FGFR4 inhibitors which can be covalently bound to the two cysteines Cys552 and Cys477 in FGFR4.

Synthetic route of generic FGFR covalent inhibitor PRN1371

The invention relates to a synthetic route of a generic FGFR covalent inhibitor PRN1371, and belongs to the field of medicinal chemistry. The synthetic route steps of the PRN1371 comprise 11 steps, purification of a product can be achieved through simple operation of various intermediates in the aftertreatment process, the problems that the product is difficult to separate, the purification operation yield is low and the like are solved, and industrial production is facilitated. The invention aims to provide a synthetic route of the FGFR irreversible covalent inhibitor PRN1371, and the methodhas the advantages of few synthesis steps, simple operation, high yield, reduction of the production cost, and provision of a new synthesis idea for the industrial production of PRN1371.

ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.